---

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):		July 17, 2006

Lifeline Therapeutics, Inc.
__________________________________________
(Exact name of registrant as specified in its charter)

Colorado	000-30489	84-1097796
_____________________ (State or other jurisdiction	_____________ (Commission	______________ (I.R.S. Employer
of incorporation)	File Number)	Identification No.)
6400 S. Fiddler's Green Circle, Suite 1970, Englewood, Colorado		80111
_________________________________ (Address of principal executive offices)		___________ (Zip Code)

Registrant’s telephone number, including area code:		720-488-1711

Not Applicable
______________________________________________
Former name or former address, if changed since last report

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

Item 7.01 Regulation FD Disclosure.

On July 17, 2006, Lifeline Therapeutics, Inc. issued a press release entitled "Lifeline Therapeutics, Inc. Announces Distribution of Protandim in CVS/pharmacy Stores Nationwide". The press release is attached as Exhibit 99.1 hereto.

Item 9.01 Financial Statements and Exhibits.

Press release dated July 17, 2006, entitled "Lifeline Therapeutics, Inc. Announces Distribution of Protandim in CVS/pharmacy Stores Nationwide".

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		Lifeline Therapeutics, Inc.
July 19, 2006		By:		Stephen K. Onody
				Name: Stephen K. Onody
				Title: CEO

---

Exhibit Index

Exhibit No.		Description
99.1		Press release dated July 17, 2006, entitled "Lifeline Therapeutics, Inc. Announces Distribution of Protandim in CVS/pharmacy Stores Nationwide".

LIFELINE THERAPEUTICS, INC. ANNOUNCES DISTRIBUTION OF
PROTANDIM^® IN CVS/PHARMACY STORES NATIONWIDE

DENVER, Colorado – Lifeline Therapeutics, Inc. (OTCBB: LFLT), today announced that Protandim^® will be carried in CVS/pharmacy stores nationwide beginning in August. Protandim, a dietary supplement clinically proven to increase the body’s natural antioxidant defenses and combat oxidative stress, will be sold at more than 6,100 locations in the CVS drugstore chain throughout the U.S., including the Sav-on and Osco stores recently acquired by CVS.

“By making Protandim available at CVS/pharmacy, we’ve greatly expanded our reach and are able to offer more customers the cellular health and healthy aging benefits of this fundamentally new approach to antioxidant therapy,” said Stephen Onody, Lifeline Therapeutics CEO. “Through the CVS partnership, the availability of Protandim will be significantly increased.”

As a part of the launch, CVS/pharmacy will co-market Protandim through a variety of initiatives, including national print advertisements in over 800 publications, in-store signage, and off-shelf merchandising. Lifeline also plans to offer a Continuing Medical Education program to CVS pharmacists.

About Protandim^®

Protandim^® is a patent-pending dietary supplement that increases the body’s natural antioxidant protection by inducing two protective enzymes, superoxide dismustase (SOD) and catalase (CAT). These naturally occurring enzymes simply become overwhelmed by free radicals as we get older. Oxidative stress (cell damage caused by free radicals) occurs as a person ages, when subjected to environmental stresses or as an associated factor in certain illnesses. TBARS are laboratory markers for oxidative stress in the body. New data from a scientific study in men and women show that after 30 days of taking Protandim^®, the level of circulating TBARS decreased an average of 40 percent, with this decrease shown to be maintained at 120 days. Protandim^® strengthens a person’s defenses against oxidative stress by increasing the body’s natural antioxidant enzymes. For more information, please visit the Protandim^® product web site at www.protandim.com.

About Lifeline Therapeutics, Inc.

Lifeline Therapeutics, Inc. markets Protandim^®. Lifeline Therapeutics is committed to helping people achieve health and wellness for life. For more information, please visit the Company’s web site at www.lifelinetherapeutics.com.

About CVS/pharmacy

CVS/pharmacy, America’s largest retail pharmacy, is committed to serving the healthcare needs of all customers by being the easiest pharmacy for customers to use, both in its 6,100+ stores and online at CVS.com. General information about CVS is available at http://investor.cvs.com, as well as www.cvs.com/pressroom.

Except for historical information contained herein, this document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and applicable common law. These statements involve known and unknown risks and uncertainties that may cause the Company’s actual results or outcomes to be materially different from those anticipated and discussed herein. Further, the Company operates in industries where securities values may be volatile and may be influenced by regulatory and other factors beyond the Company’s control. Other important factors that the Company believes might cause such differences include the Company’s limited cash flow and the rapid development of technology, lack of liquidity for the Company’s common stock, working capital shortages, the length of time for scientific advances to reach the market (if they ever reach the market), among other risks. In assessing forward-looking statements contained herein, readers are urged to carefully read all cautionary statements contained in the Company’s filings with the Securities and Exchange Commission.

# # #

CONTACTS: